Head of the department of Nuclear Medicine at the University Hospital in Nantes and ICO-Gauducheau, and co-leader of the Nuclear Oncology Research team of the Centre de Recherche en Cancérologie de Nantes-Angers (CRCNA), Françoise Kraeber-Bodéré has been particularly involved over the last ten years in the design of academic multicentre translational clinical trials assessing innovative radiopharmaceuticals in oncology, in close collaboration with industrial partners and cooperative groups.

These trials demonstrated clinical benefits of radioimmunotherapy in lymphoma, leading in 2009 to the “Victoires de la Médecine” award in Oncology. Françoise Kraeber-Bodéré is an expert of the oncology committee of the French Society of Nuclear Medicine (SFMN) and of the therapy committee of the European Association of Nuclear Medicine.

She is on the scientific board of the French Lymphoma research group Goelams and expert for PET and lymphoma for HAS and INCa. She obtained several grants and was principal investigator of numerous clinical trials of radioimmunotherapy, PET and immuno-PET. Françoise Kraeber-Bodéré has participated in more than 130 international publications and has been the project leader of the IRON Labex since 2011.